Research view
Switch to patient viewEndometrial cancer: trials that stopped early
Trials on Endometrial cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
57 stopped trials give a reason in the registry, latest registry update first.
Terminated
PRO1107 in Patients With Advanced Solid Tumors
Reason given in the registry “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Oct 2026.
- Ended
- Aug 2025
- Phase
- Phase 1/2
- Run by
- Genmab
- Registry record
- NCT06171789
Terminated
Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer
Reason given in the registry “recruitement failure”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2026.
- Ended
- Aug 2024
- Run by
- Centre Hospitalier Metropole Savoie
- Registry record
- NCT05833321
Terminated
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Reason given in the registry “Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Aug 2026.
- Ended
- Mar 2026
- Phase
- Phase 1
- Run by
- Boundless Bio, Inc.
- Registry record
- NCT05827614
Terminated
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
Reason given in the registry “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2026.
- Ended
- Apr 2025
- Phase
- Phase 1/2
- Run by
- NextCure, Inc.
- Registry record
- NCT05572684
Terminated
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Reason given in the registry “The Sponsor has made a strategic decision to stop the development of GEN1047.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.
- Ended
- Mar 2026
- Phase
- Phase 1/2
- Run by
- Genmab
- Registry record
- NCT05180474
Terminated
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Reason given in the registry “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.
- Ended
- May 2025
- Phase
- Phase 1/2
- Run by
- NuCana plc
- Registry record
- NCT05714553
Terminated
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
Reason given in the registry “SOC changed and low enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Jul 2026.
- Ended
- Jul 2024
- Phase
- Phase 2
- Run by
- University of Maryland, Baltimore
- Registry record
- NCT04527900
Terminated
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Reason given in the registry “no enough enrolled patients”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2026.
- Ended
- Feb 2026
- Phase
- Phase 2/3
- Run by
- Xiaojun Chen
- Registry record
- NCT05316467
Terminated
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Reason given in the registry “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2026.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT04458259
Terminated
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
Reason given in the registry “Funding issue”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Jun 2026.
- Ended
- Jan 2025
- Phase
- Phase 2
- Run by
- University of Oklahoma
- Registry record
- NCT05523440
Withdrawn
AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
Reason given in the registry “Molecule not available from the laboratory”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2026.
- Phase
- Phase 1/2
- Run by
- Centre Leon Berard
- Registry record
- NCT07146919
Terminated
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
Reason given in the registry “PI request”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Mar 2026.
- Ended
- May 2025
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT05036681
Terminated
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Reason given in the registry “The study was terminated by sponsor based on the adverse event profile.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Feb 2026.
- Ended
- Jan 2026
- Phase
- Phase 1
- Run by
- Accent Therapeutics
- Registry record
- NCT06625515
Suspended
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Reason given in the registry “Funding and drug supply to continue the study are pending.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Feb 2026.
- Phase
- Phase 1
- Run by
- Dana-Farber Cancer Institute
- Registry record
- NCT03065062
Withdrawn
Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer
Reason given in the registry “slow accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Feb 2026.
- Ended
- Jul 2026
- Run by
- City of Hope Medical Center
- Registry record
- NCT07226102
Withdrawn
Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer
Reason given in the registry “Study withdrawn due to lack of accrual.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Feb 2026.
- Ended
- Jun 2025
- Run by
- University of Oklahoma
- Registry record
- NCT05850663
Terminated
A Study of PHN-010 in Patients With Advanced Solid Tumors
Reason given in the registry “The study was terminated by Sponsor for strategic reasons.”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jan 2026.
- Ended
- Sept 2025
- Phase
- Phase 1
- Run by
- Pheon Therapeutics
- Registry record
- NCT06457997
Terminated
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
Reason given in the registry “This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Jan 2026.
- Ended
- Jul 2025
- Phase
- Phase 2
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT06865677
Terminated
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Reason given in the registry “Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Jan 2026.
- Ended
- Nov 2025
- Phase
- Phase 2
- Run by
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Registry record
- NCT05481645
Terminated
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Reason given in the registry “Copanlisib development was discontinued by Bayer following withdrawal of copanlisib in relapsed follicular lymphoma in November 2023.”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Jan 2026.
- Ended
- Dec 2025
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT05082025
Terminated
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Reason given in the registry “A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Jan 2026.
- Ended
- Dec 2025
- Phase
- Phase 1
- Run by
- Fusion Pharmaceuticals Inc.
- Registry record
- NCT03746431
Terminated
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Reason given in the registry “No enough participants”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Dec 2025.
- Ended
- Dec 2025
- Phase
- Phase 2/3
- Run by
- Fudan University
- Registry record
- NCT05454358
Terminated
Study of ART0380 in Patients With Biologically Selected Solid Tumors
Reason given in the registry “Sponsor decision, not for reasons affecting the benefit-risk balance.”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Nov 2025.
- Ended
- May 2025
- Phase
- Phase 2
- Run by
- Artios Pharma Ltd
- Registry record
- NCT05798611
Terminated
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Reason given in the registry “Recruitment challenges”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Oct 2025.
- Ended
- Aug 2024
- Phase
- Phase 2
- Run by
- Tempus AI
- Registry record
- NCT05169437
Terminated
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Reason given in the registry “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2025.
- Ended
- Aug 2024
- Phase
- Phase 1
- Run by
- Incyte Corporation
- Registry record
- NCT04272034
Withdrawn
18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
Reason given in the registry “Drug cannot be produced and scanner down.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Oct 2025.
- Phase
- Phase 2
- Run by
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT05483023
Terminated
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Reason given in the registry “Closed early due to low enrollment rates”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Oct 2025.
- Ended
- Oct 2024
- Phase
- Phase 2
- Run by
- Virginia Commonwealth University
- Registry record
- NCT05263492
Terminated
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Reason given in the registry “This study was terminated as a result of Sponsor portfolio reprioritization.”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Sept 2025.
- Ended
- Apr 2025
- Phase
- Phase 1
- Run by
- NiKang Therapeutics, Inc.
- Registry record
- NCT06264921
Terminated
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Reason given in the registry “Sponsor Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Sept 2025.
- Ended
- Feb 2025
- Phase
- Phase 1/2
- Run by
- Bolt Biotherapeutics, Inc.
- Registry record
- NCT04278144
Terminated
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Reason given in the registry “Due to the adjustment of our company's research and development strategy, we are now prematurely terminating this project.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Aug 2025.
- Ended
- Aug 2025
- Phase
- Phase 2/3
- Run by
- Bio-Thera Solutions
- Registry record
- NCT06321068
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.